



NORRIS
MEDICINES LIMITED



Factory : Plot No. 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date:10th August, 2023

To
The Manager
Department of Corporate Services
BSE Ltd.
Dalal Street, Fort
Mumbai – 400 001

Sub. - : Outcome of Board Meeting

Ref. - : Scrip Code - 524414

Dear Sir / Madam,

The Board of Directors at their Meeting held on 10th August, 2023, has approved the Un-audited financial results for the Quarter ended 30th June 2023. As per Regulation 33 of Listing Regulations, the Financial Results and Limited Review Report are enclosed herewith for your records.

The meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 04:30 P.M.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours faithfully,

For Norris Medicines Limited

Vimal D. Shah
Managing Director
DIN: 01506655



Encl: As above

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No.,L24230GJ1990PL086581

Rs. In La

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Previous accounting
		30.06.2023	31.03.2023	30.06.2022	year ended 31.03.2023
		Unaudited	Audited	Unaudited	Audited
1	(a) Revenue from Operations	94.64	121.31	95.31	835.82
	(b) Other Income	0.00	1.19	-	1.45
	Total Income From Operations (Net)	94.64	122.49	95.31	837.26
2	Expenses				
	a. Cost of Materials Consumed	113.08	(37.67)	35.77	323.43
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	(76.84)	16.34	(16.63)	12.85
	c. Employee Benefit Expenses	59.74	60.88	44.14	229.94
	d. Finance Costs	8.61	36.94	9.28	150.03
	e. Depreciation and Amortisation Expense	14.32	17.56	15.14	62.98
	f. Other expenditure	37.22	27.20	51.53	177.36
	Total Expenses	156.13	121.25	139.23	956.59
3	Profit/ Loss before Tax (1-2)	-61.49	1.24	-43.92	-119.33
4	Tax Expense				
	a: Current Tax	0	0.00	0	0.00
	b: Deferred Tax	0	55.62	0	55.62
5	Profit / Loss after Tax	-61.49	-54.38	-43.92	-174.95
6	Other Comprehensive Income				
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-61.49	-54.38	-43.92	-174.95
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.61	-0.54	-0.44	-1.75

Notes:

1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10/08/2023. The above results have been subjected to Audit by the Statutory Auditors of the Company.

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.

3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.06.2023

5) Previous year/ period figures have been regrouped /rearranged wherever necessary to make them comparable with current period figures.

For Norris Medicines Limited

Vimal D Shah
Managing Director



Date: 10.08.2023
Place: Ankleshwar

BAHEDIA & ASSOCIATES

CHARTERED ACCOUNTANTS



SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Towards Valia Road,
GIDC Estate, ANKLESHWAR - 393 002. ☎ : (02646) 221708

CA. B. L. Bahedia
(B.Com., D.T.P., LL.B., FCA.)

Mobile No. : +91 98241 36264, 97252 20412
E-mail : bbahedia@yahoo.com/gmail.com
Web : www.bahediaassociates.icai.org.in

Ref. No. :

Date :

Review Report to Bombay Stock Exchange

We have reviewed the accompanying statement of unaudited financial results of NORRIS LIMITED COMPANY for the period ended 30th June, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

PLACE: Ankleshwar
DATE: 10/08/2023

For, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
[FRN-114421W]



(CA. B.L.BAHEDIA)
PROPRIETOR
(M.NO.048066)
UDIN: - 23048066BGWDAF5878